| Entries |
| Document | Title | Date |
|---|
| 20080241864 | EIA for monitoring legionella pneumophila presence in water samples - A qualitative and quantitative EIA for detecting | 10-02-2008 |
| 20080286818 | BLOOD SAMPLE HANDLING METHODS FOR IMPROVED ASSAYS FOR MYELOPEROXIDASE - The invention provides a method for determining concentration of myeloperoxidase (MPO) in a human blood sample comprising: (a) providing a human peripheral blood sample stored under MPO preservation conditions; and (b) determining concentration of MPO in a plasma sample derived from the human peripheral blood sample. In a preferred embodiment, the MPO preservation conditions used in the invention comprise storage of the human peripheral blood sample in a plasma collection tube containing a leukocyte MPO secretion inhibitor. In this embodiment, the leukocyte MPO secretion inhibitor is preferably ethylene diamine tetraacetic acid (EDTA). The assays used in the inventive methods can comprise any clinically useful assay for determining MPO plasma concentration, including sandwich and competitive immunoassays, clinical chemistry assays and enzymatic assays. | 11-20-2008 |
| 20080286819 | Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof - The present invention provides reagents, methods and systems for predicting the cytotoxic activity of an antibody or variant thereof comprising: determining a binding affinity of the antibody or variant thereof to a Fc activating receptor; determining a binding affinity of the antibody or variant thereof to a Fc inhibitory receptor, and calculating the ratio of said activating binding affinity to said inhibitory binding affinity (A/I ratio), wherein the magnitude of said ratio is an indication of the cytotoxic activity of the antibody or variant thereof. The present invention also provides purified modified antibodies having altered A/I ratios as compared to the unmodified antibodies. | 11-20-2008 |
| 20090053743 | ANTI-ANTIBODY REAGENT - An anti-antibody reagent for use in a competitive or sandwich simplex or multiplex assay, said reagent comprising one or more labeled anti-antibodies for the primary antibodies to be determined in the assay, the reagent further comprising a corresponding unlabeled anti-antibody in an excess or near excess concentration with respect to their binding partners. | 02-26-2009 |
| 20090068692 | MARKER FOR PROLONGED RUPTURE OF MEMBRANES - The present invention relates to amniotic fluid specific polypeptide and a method for detecting rupture of the amniotic membranes. In particular the invention provides a marker for prolonged rupture of the membranes (PROM), which marker consists essentially of polypeptides of approximately 75 kDa, 20 kDa and 50 kDa as determined by 4-15% gradient SDS-PAGE under reducing conditions. | 03-12-2009 |
| 20090081714 | Assays - Methods and assays for monitoring the cardiac health of a subject are provided. The method involves the detection of a urotensin surrogate in a sample leading to a more accurate and reliable diagnosis of early or late stages of decompensated heart failure, heart failure, risk of a heart failur in a subject than the measurement of the cyclic peptide of urotensin alone. | 03-26-2009 |
| 20090162877 | Methods to Identify Protein Arginine Deiminase 4 Inhibitors - In accordance with one embodiment of the present disclosure, a method to identify a protein arginine deiminase 4 inhibitor is disclosed. The method includes performing a competitive assay in which a potential inhibitor compound competes with rhodamine-conjugated fluoroamidine to bind to protein arginine deiminase 4. Fluorescence is measured to determine an estimate of the amount of fluorescent protein arginine deiminase 4 that is present in the assay. | 06-25-2009 |
| 20090215095 | COMPOSITIONS AND METHODS FOR MEASURING LEVELS OF BIOACTIVE HUMAN HEPCIDIN - The invention provides compositions and methods for measuring human serum hepcidin levels. The invention provides methods for the oxidative refolding of a hepcidin polypeptide to a form that is mature, bioactive and folded as in the native configuration and molecular mass; a method for measuring the level of native, bioactive hepcidin in a vertebrate animal. | 08-27-2009 |
| 20090263839 | ACETAMINOPHEN-PROTEIN ADDUCT ASSAY DEVICE AND METHOD - The present invention describes devices and methods for detecting and measuring the amount of acetaminophen-protein adducts in a sample. | 10-22-2009 |
| 20090317844 | DIAGNOSTIC TEST FOR HEPATOCELLULAR CARCINOMA - A diagnostic test for hepatocellular carcinoma is based on increases in the concentration of two biochemical markers in a biological sample, alpha-1-acid glycoprotein (AAG) or isoforms thereof and alpha-fetoprotein (AFP) or glycoforms thereof. Levels of these markers may be performed using an immunoassay. Also disclosed is a diagnostic kit for use in these assays that comprises reagents for detecting and/or measuring in AAG and AFP in blood, serum or tissue samples. A point-of-care device for the performance of such measurements is also disclosed. | 12-24-2009 |
| 20100047831 | DIAGNOSIS OF ANTHRAX INFECTION BY DETECTION OF CAPSULAR ANTIGEN IN URINE - The present invention provides methods useful for diagnosis of anthrax by detection of capsular polypeptide in serum, urine, or other biological samples. | 02-25-2010 |
| 20100112609 | Determining and Reducing Immunoresistance to a Botulinum Toxin Therapy Using Botulinum Toxin B Peptides - The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual. | 05-06-2010 |
| 20100112610 | Determining and Reducing Immunoresistance to a Botulinum Toxin Therapy Using Botulinum Toxin B Peptides - The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual. | 05-06-2010 |
| 20100136590 | Method of Determining NT-proBNP - The invention relates to a method of determining equine NT-proBNP, or fragments thereof, comprising the steps of: providing an equine sample, contacting the sample with at least one antibody which specifically binds to equine NT-proBNP, and determining the presence and/or concentration of the equine NT-proBNP or fragments thereof existing in the sample. | 06-03-2010 |
| 20100159491 | H-FABP AS EARLY PREDICTOR OF MYOCARDIAL INFARCTION - The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of H-FABP and, optionally, myoglobin in a sample of the subject and comparing the amount of H-FABP and, optionally, myoglobin to reference amounts. | 06-24-2010 |
| 20100190192 | METHOD OF DIAGNOSING PRE-ECLAMPSIA - The present invention relates to a marker for the development of pre-eclampsia. In particular the invention provides a marker for the development of pre-eclampsia, which marker consists of a polypeptide of approximately 26.6 Kd as determined by 15-30% gradient SDS-PAGE under reducing conditions. | 07-29-2010 |
| 20100248272 | Method for identifying Smk box riboswitch modulating compounds - The invention is directed, inter alia, to a method for identifying a compound that modulates a gene expression of an mRNA molecule containing a S | 09-30-2010 |
| 20100267063 | METHODS AND APPARATUSES FOR CONDUCTING ASSAYS - Disclosed are methods for conducting assays of samples, such as whole blood, that may contain cells or other particulate matter. Also disclosed are systems, devices, equipment, kits and reagents for use in such methods. One advantage of certain disclosed methods and systems is the ability to rapidly measure the concentration of an analyte of interest in blood plasma from a whole blood sample without blood separation and hematocrit correction. | 10-21-2010 |
| 20100323377 | BIOCHEMICAL MARKERS FOR CVD RISK ASSESSMENT - A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a protein of an atherosclerotic plaque such as lumican, versican, perlecan, decorin, biglycan, collagen type III, CRP, ApoE, or elastin, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events. | 12-23-2010 |
| 20110065135 | LIPOSOME COMPOSITION, ITS PRODUCTION PROCESS, AND METHOD FOR ANALYZING ANALYTE USING THE SAME - A liposome composition capable of including a chemical substance such as an electrochemiluminescent substance in an internal aqueous phase of the liposome at a higher concentration, and a production method thereof, as well as an analytical method of an analyte that enables an analyte to be analyzed with a high sensitivity using the liposome composition are provided. In a liposome composition containing a liposome, and a chemical substance enclosed in an internal aqueous phase of the liposome, a lipid bilayer composing the liposome has a positive or negative charge, and the chemical substance has a charge opposite to the charge of the lipid bilayer. | 03-17-2011 |
| 20110076702 | RECOMBINANT 12-KDA PROTEIN USEFUL FOR THE DETECTION OF RESPIRATORY ALLERGIES - The present invention discloses the detection of an important 12K-Da protein having cross-reactivity amongst different prevalent allergenic grasses and fungi can be useful for detection of respiratory allergies. Conventionally, the whole extracts that are used for diagnosis are unable to specifically detect the causative agents. In addition, they are also responsible for additional non-specific sensitivities in patients to other components present in the extract. If a single cross-reactive protein is available, it can replace large number of extracts used for detection of raised IgE levels in allergy by ELISA, immunoblotting and the likes. Further, number of pricks would be reduced and this would benefit both patient and clinicians. It is further realized that production of such a protein by recombinant methods can lead to its availability in pure form and bulk amounts required for routine diagnosis. | 03-31-2011 |
| 20110076703 | CONCENTRATION ASSAY - A method of determining the concentration of at least one analyte in a plurality of samples by sequentially subjecting each sample to an analysis cycle comprises contacting the sample or a sample-derived solution with a sensor surface supporting a species capable of specifically binding the analyte or an analyte-binding species, detecting the amount of binding to the sensor surface, and regenerating the sensor surface to prepare it for the next analytical cycle, and based on the detected binding to the sensor surface determining the concentration of analyte in each sample using virtual calibration data calculated for each analysis cycle from real calibration data obtained by contacting the solid phase with samples containing known concentrations of analyte. | 03-31-2011 |
| 20110124020 | Methods for Detecting Antibodies - Methods for detection of any antibody utilizing a standardized approach applicable to any antibody which provides highly specific assays specific for individual or multiple antibodies. The methods enable improved pharmacokinetic analysis during development and clinical use of antibody-based therapies as well as determination of diagnostic and/or prognostic factors. | 05-26-2011 |
| 20110177537 | Method and System for Measuring a Sample to Determine the Presence of and Optionally Treat a Pathologic Condition - The present invention provides diagnostic in vitro methods as well as kits and devices to be used in the methods of the present invention for diagnosis or prognosis of a pathologic condition characterized by the presence/absence of an endogenous hormone and/or hormone analog(s) thereof involved in diabetes or metabolic syndrome. The methods comprise a quantitative separation of at least those analytes of interest whose common presence interferes with measuring the presence/absence or concentration of one of the analytes of interest by a subsequent analytical method. | 07-21-2011 |
| 20110223624 | IMMUNOASSAY FOR DETECTION OF NEUROTOXIC AMINO ACID ASSOCIATED WITH NEUROLOGICAL DISORDERS - An immunoassay for screening a sample to detect the presence of β-N-methylamino-L-alanine (BMAA) is disclosed. Antibodies specific for BMAA are disclosed. Antibodies that bind to BMAA on immunoblots are disclosed. Immunoassays and kits to detect the presence of BMAA in a sample by contacting the sample with an antibody that binds to BMAA, and detecting the antibody bound to the sample, are disclosed. Immunoassays and kits for screening for the presence of BMAA in a subject by analyzing a tissue sample obtained from the subject to detect the present of BMAA in the tissue sample, where the presence of BMAA in the tissue sample indicates exposure of the subject to an environmental source of BMAA, are disclosed. Immunoassays and kits for detecting an environmental source of BMAA, by screening an environmental sample to detect the presence of BMAA in the sample, wherein the presence of a detectable amount of BMAA in the sample indicates the sample is an environmental source of BMAA, are disclosed. | 09-15-2011 |
| 20110269159 | REAGENTS FOR REDUCING LEUKOCYTE INTERFERENCE IN IMMUNOASSAYS - Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample such as a whole blood sample with one or more leukocidal reagents that reduce or eliminate the metabolic activity of leukocytes, and performing an immunoassay on the amended sample to determine the concentration of analyte in the sample. Preferably, the sample is amended with one or more enzymes and optionally one or more enzyme substrates and cofactors. | 11-03-2011 |
| 20110306070 | MAGNETIC BEADS FOR REDUCING LEUKOCYTE INTERFERENCE IN IMMUNOASSAYS - Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immuno sensor. | 12-15-2011 |
| 20110318765 | METHOD FOR PRE-TREATING SAMPLE CONTAINING GLYCATED HEMOGLOBIN - There are provided a pre-treatment technique for a glycated hemoglobin-containing sample, which is a simple and convenient treatment, is free from problems in storage stability and environmental aspects, and is capable of exposing an epitope sufficiently in a short time; and an method for an immunological assay of glycated hemoglobin using this technique. | 12-29-2011 |
| 20120009608 | BIOMARKER FOR THE MONITORING AND PROGNOSIS OF CHRONIC MYELOPROLIFERATIVE DISORDERS - The invention provides a method for monitoring the progression of a myeloproliferative disease, particularly Polycythemia Vera (PV) and Essential Thrombocythemia (ET), or the response to pharmacological treatment with JAK2 inhibitors in a patient diagnosed positive for the same disease, or a method for predicting thrombotic events in a patient affected by the same myeloproliferative diseases, based on the measurement of PTX3 concentration in a blood, plasma or serum sample. | 01-12-2012 |
| 20120034631 | ANTI-LYSOPHOSPHOLIPID ANTIBODY DESIGN USING ANTIBODY STRUCTURES - The present invention provides crystalline forms of an anti-LPA antibody or fragment thereof, which may further comprise a lipid ligand of said antibody and/or salts, metals, or co-factors. Methods for making such crystals and co-crystals are provided, as are methods of using structural information in antibody design or optimization. Methods for designing a humanized antibody to a lipid are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Optimized variant anti-LPA antibodies are also provided. | 02-09-2012 |
| 20120034632 | TWO-PHASE OPTICAL ASSAYS FOR ANALYTES OF NO INTRINSIC OPITCAL CONTRAST - Methods and kits for performing a two-phase optical assay for one or more than one analyte without intrinsic optical contrast in a sample are disclosed. The method requires use of a functionalized microparticle immobilized with two or more than functional components and an additional set of one or more than one functional component. The assay can be performed in one single container and does not need a wash step. | 02-09-2012 |
| 20120045782 | IMATINIB IMMUNOASSAY - Novel conjugates and immunogens derived from imatinib and monoclonal antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of imatinib or its pharmacologically active salts in biological fluids. | 02-23-2012 |
| 20120135434 | MCPP IMMUNOASSAY - The invention describes a practical and robust multi-antibody approach to the sensitive immunodetection and determination of the drug of abuse m-chlorophenyl piperazine (mCPP). The invention also describes methods and kits for mCPP detection in an in vitro sample. | 05-31-2012 |
| 20120202229 | Immunoassay tracer reagents and methods for measuring the amount of native human bioactive hepcidin - The invention provides compositions and methods for measuring human serum hepcidin levels. The invention provides methods for the oxidative refolding of a hepcidin polypeptide to a form that is mature, bioactive and folded as in the native configuration and molecular mass; a method for measuring the level of native, bioactive hepcidin in a vertebrate animal. | 08-09-2012 |
| 20120202230 | Liquid Reagent of Thyroid Hormone-Immobilized Carrier and Use Thereof - A liquid reagent of a stabilized thyroid hormone-immobilized carrier, by which a thyroid hormone can be measured easily in a short time and at low cost, is provided. The liquid reagent of a thyroid hormone-immobilized carrier according to the present invention includes: a thyroid hormone-immobilized carrier; and a solvent, and a pH of the solvent containing the thyroid hormone-immobilized carrier is in a range from 8.7 to 11.5. The detection of a thyroid hormone using the liquid reagent of the present invention can be carried out by competitively binding a thyroid hormone in a sample and the thyroid hormone-immobilized carrier in the liquid reagent with an anti-thyroid hormone antibody and detecting a composite of the thyroid hormone-immobilized carrier and the anti-thyroid hormone antibody. | 08-09-2012 |
| 20120214184 | DOXORUBICIN IMMUNOASSAY - Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids. | 08-23-2012 |
| 20120219977 | SEQUENCES, ANTIBODIES, METHODS AND KITS FOR DETECTION AND IN VITRO ASSAY OF PERIOSTIN, IN ORDER TO PROVIDE A DIAGNOSIS, FOLLOW-UP OR PROGNOSIS OF DISEASES AND BIOLOGICAL PHENOMENA INVOLVING PERIOSTIN - Detection sequences of periostin having from 6 to 30 amino acids and which include all or part of peptide sequence SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3, or a homologous peptide sequence. Antibodies suitable for specifically recognizing minimally one of these detection sequences, including an anti-periostin antibody, are disclosed. Periostin detection and dosage processes and kits that use these antibodies are also disclosed. A periostin marker for early diagnosis, tracking and prognosis of pathologies that involve periostin, including benign osteolysis such as inflammatory diseases, including osteoarticular diseases, and malignant osteolysis, such as cancers with bone metastases, is provided. | 08-30-2012 |
| 20120225443 | STABILIZED STANDARDS FOR BUSULFAN IMMUNOASSAY - Use of busulfan amide as stabilized standards in immunoassays for quantifying the amount of busulfan in samples of human biological fluids, methods for carrying out said immunoassay and kits for use in said immunoassay. | 09-06-2012 |
| 20120237959 | TUMOR ENDOTHELIAL MARKER 5-ALPHA MOLECULES AND USES THEREOF - The present invention provides Tumor Endothelial Marker 5α (TEM5α) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5α polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5α polypeptides. | 09-20-2012 |
| 20120252041 | METHOD OF PROGNOSIS - The present invention relates to the use of soluble CD163 as a prognostic marker for the assessment of the risk for contracting a disorder, in particular for contracting diabetes and/or a liver disorder. The invention also relates to the use of CD163 as a prognostic marker for assessing lifetime expectancy. | 10-04-2012 |
| 20120264148 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Dashurin as a diagnostic and prognostic biomarker in renal injuries. | 10-18-2012 |
| 20120295287 | PREPARING HAPTEN-SPECIFIC ANTIBODIES AND THEIR APPLICATION FOR IMMUNODIAGNOSTICS AND RESEARCH - This document provides methods and materials related to detecting neurotransmitters and other biologically active small molecules. For example, methods for detecting and measuring hapten levels in a biological sample using antibodies specific for conjugated haptens are provided. | 11-22-2012 |
| 20120322089 | SENSITIVE AND GENERIC ANTIBODIES AND MULTIPLE APPLICATIONS - The invention relates to the detection and quantification of carbamazepine drugs and their metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications. | 12-20-2012 |
| 20130017563 | Diagnosis of Gluten-Induced Autoimmune DiseasesAANM Korponay-Szabo; IlmaAACI BudapestAACO HUAAGP Korponay-Szabo; Ilma Budapest HUAANM Fesus; LaszloAACI DebrecenAACO HUAAGP Fesus; Laszlo Debrecen HUAANM Bagossi; PeterAACI DebrecenAACO HUAAGP Bagossi; Peter Debrecen HUAANM Csosz; EvaAACI DebrecenAACO HUAAGP Csosz; Eva Debrecen HUAANM Kiraly; RobertAACI DebrecenAACO HUAAGP Kiraly; Robert Debrecen HUAANM Simon-Vecsei; ZsofiaAACI DebrecenAACO HUAAGP Simon-Vecsei; Zsofia Debrecen HUAANM Maki; MarkkuAACI TampereAACO FIAAGP Maki; Markku Tampere FIAANM Bagossi; PeterneAACI DebrecenAACO HUAAGP Bagossi; Peterne Debrecen HU - The invention relates to selective diagnosis of gluten-induced autoimmune diseases by binding assays utilizing the main celiac epitope present on proteins of the transglutaminase family. | 01-17-2013 |
| 20130045493 | DIAGNOSIS AND TREATMENT OF GLUTEN-INDUCED AUTOIMMUNE DISEASES - The invention relates to selective diagnosis of gluten-induced autoimmune diseases by binding assays utilizing the main celiac epitope present on proteins of the transglutaminase family. | 02-21-2013 |
| 20130059318 | ANTI-IGA1 ANTIBODY - An object of the present invention is to provide a monoclonal antibody which is effective for diagnosing IgA nephropathy and specifically recognizes and binds to a hinge region of a polypeptide encoded by a heavy chain gene of immunoglobulin A1 that comprises a serine/threonine-linked sugar chain to which galactose is not bound. According to the present invention, it is possible to provide a monoclonal antibody or an antibody fragment thereof that specifically recognizes and binds to a hinge region of a polypeptide encoded by a heavy chain gene of immunoglobulin A1 that comprises a serine/threonine-linked sugar chain to which galactose is not bound, to provide a diagnostic agent using the antibody or the antibody fragment thereof, and to provide a therapeutic agent comprising the antibody or the antibody fragment thereof as an active ingredient. | 03-07-2013 |
| 20130084586 | RAPID, SPECIFIC AND SENSITIVE IMMUNOASSAYS FOR THE DETECTION OF HIGHLY VARIABLE GRAM NEGATIVE BACTERIAL ANTIGENS - Methods for the detection, identification and quantification of gram negative bacteria and gram negative bacterial antigens are rapid, efficient and highly specific. Compositions for the detection and identification of highly variable serogroups are provided. | 04-04-2013 |
| 20130122529 | HbF AND A1M AS EARLY STAGE MARKERS FOR PREECLAMPSIA - A method for diagnosing or predicting the risk of developing preeclampsia by measuring the level of A1 M and one or more of the compounds HbA, HbF in a sample and comparing the obtained values with reference values. By using a combination of information relating to A1 M and HbF improved diagnose or prediction is observed. | 05-16-2013 |
| 20130130287 | MARKERS FOR ACUTE KIDNEY INJURY - Provided are methods and compositions for predicting the development of kidney disease, including acute kidney injury. In certain aspects and embodiments the provided methods and compositions are particularly useful for predicting kidney injury following an event likely to cause kidney injury and/or kidney failure in a patient, such as a cardiac surgery, e.g., a surgery involving a cardiopulmonary bypass (CPB), such as a coronary artery bypass graft surgery. In some embodiments, the higher the urinary hepcidin-to-urinary creatinine ratio (uHep/uCr) at 6-24 hours following initiation of CPB, the lower is the risk for development of AKI determined by RIFLE criteria in the ensuing four to five days. Conversely, the higher the urinary NGAL to urinary creatinine ratio (uNGAL/uCr) at 6-24 hours following initiation of CPB, the higher is the risk of developing CPB-mediated AKI over the same time period. | 05-23-2013 |
| 20130203092 | Lectin Assay for Assessing Glycoforms as an Early Marker in Disease - The present invention provides methods, compositions, apparatus, and kits for assessing glycoforms of proteins as a biomarker for disease. A purified recombinant form of lectin is used as a detector molecule to specifically label target sugars expressed in disease states. The high affinity of recombinant lectin allows for automation of assays that would be used in the diagnosis of diseases such as, but not limited to, cancer or liver disease. | 08-08-2013 |
| 20130210040 | DIAGNOSTIC METHOD - It has been demonstrated that the level of sST2 increases in pregnant females suffering from pre-eclampsia. Accordingly, the level of sST2 in a pregnant female can be used to assess risk of developing pre-eclampsia. | 08-15-2013 |
| 20130260402 | ANTHRAX CARBOHYDRATES, SYNTHESIS AND USES THEREOF - The present invention presents the isolation, characterization and synthesis of oligosaccharides of | 10-03-2013 |
| 20130273580 | ELISA ASSAY KIT, ELISA FOR DETERMINING DESMOSINE LEVELS FROM URINE SAMPLES AND DIAGNOSTIC URINE ASSAYS FOR ANEURYSMS - Improved ELISA assay formats are described that provide for effective measurement of desmosine, an elastin degradation product, in urine samples. The urine samples can be effectively introduced into the assay with little or no sample preparation. The competitive ELISA assay based on high titer polyclonal antibodies is suitable for commercial application. Desirable antibodies can be generated using desmosine bound to a protein or the like using a protein crosslinking agent. The desmosine assay are found to be useful for the diagnosis of aortic aneurysms in which desmosine levels of patients with aortic aneurysms have been found to be significantly elevated relative to a control group. | 10-17-2013 |
| 20130273581 | HAPTENS AND IMMUNOREACTIVE AGENTS AND USE THEREOF FOR PRODUCING FAMILY ANTIBODIES AND IMMUNOASSAYS FOR QUINOLONES - The invention relates to haptens, immunogens and secondary immunoreactive agents, to the use thereof for producing wide-spectrum antibodies against quinolone-type antibiotics, to the application thereof to immunochemical analysis techniques, and to a kit enabling the detection of said antibiotics in biological samples from food products of animal origin. | 10-17-2013 |
| 20130280740 | Methods for Detecting Symmetrical Dimethylarginine - Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases. | 10-24-2013 |
| 20130288279 | SPECIFIC A1AT MONOCLONAL ANTIBODIES FOR DETECTION OF ENDOMETRIOSIS - Provided herein are monoclonal antibodies with a high binding affinity to isoforms of alpha 1-antitrypsin (A1AT), hybridoma cells producing the same, and their uses in diagnosing and/or detecting endometriosis from a serum sample of a subject suspicious of having endometriosis or a subject under health examination. | 10-31-2013 |
| 20130295592 | DETERMINATION OF TOTAL ANALYTE CONCENTRATION - Methods and reagents are disclosed for determining a total amount of an analyte in an unknown sample suspected of containing the analyte in the presence of endogeneous interfering substances. The methods involve measuring an amount [Y] of the portion of the analyte in the unknown sample that is bound by endogeneous binding substances employing an assay for the analyte. An amount [Z] of analyte in the unknown sample that is not bound by endogeneous binding substances is determined by the formula: [Z]=a[Y]+b, wherein “a” and “b” are predetermined by conducting the assay on samples containing known amounts of the analyte but substantially free from endogeneous interfering substances. Adding [Y] and [Z] yields the total amount [X] of the analyte in the unknown sample. | 11-07-2013 |
| 20130295593 | TRUNCATED HUMAN VITAMIN D BINDING PROTEIN AND MUTATION AND FUSION THEREOF AND RELATED MATERIALS AND METHODS OF USE - Vitamin D binding proteins (DBP), in particular truncated DBP and mutated, truncated DBP, as well as fusion proteins thereof, nucleic acid molecules encoding same, vectors, host cells, and methods, kits and solid supports for determining the total amount of 25-hydroxy vitamin D | 11-07-2013 |
| 20130344516 | ARMET AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein ARMET in said sample in vitro. | 12-26-2013 |
| 20140024056 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF - The present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins. The surrogate compounds of the invention typically comprise antigenic epitopes (one of which carries a post-translational modification) that are tethered by a flexible and hydrophilic linker. The resulting compound behaves like a surrogate of the post-translationally modified protein because it preserves the character of the included antigens and allows recognition by specific antibodies targeting the individual antigens. The surrogate compounds may be prepared by covalently joining two or more polypeptide epitopes using one or more linkers, wherein at least one of the epitopes comprises a post-translational modification. In one aspect, the surrogate compounds of the invention comprise a C-terminal epitope and a glycated epitope of human CD59. The inventive methods allow quantification of the levels of glycated CD59 in the serum in human subjects, particularly those with diabetes or pre-diabetes. This technological platform of post-translationally modified protein surrogates can be applied to other diseases associated with post-translationally modified proteins (e.g., autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus). In another aspect, the invention provides antibodies that bind specifically to the compounds of the invention and methods for producing such antibodies. | 01-23-2014 |
| 20140024057 | SYSTEMS AND METHODS FOR DETECTING ANIMAL PREGNANCY - Testing systems and methods are disclosed for detecting a pregnancy marker of an animal. A test kit may include a first standard with a first concentration of the marker, a second standard with a second concentration of the marker lower than the first concentration, and at least three test surfaces coated with a biomolecular recognition element selected to bind with the marker. The test may also include a reagent solution with a conjugated biomolecular recognition element that binds with the marker, and a visual indicator that produces a visually detectable change when reacting with the conjugated biomolecular recognition element bound to each test surface. A detectable change generated by the marker from the sample with an intensity greater than the first concentration yields a pregnant result, lower than the second concentration yields a not pregnant result, and between the first and second concentrations yields a retest result. | 01-23-2014 |
| 20140051098 | Thrombospondin Fragments and Uses Thereof in Clinical Assays for Cancer and Generation of Antibodies and Other Binding Agents - The invention relates to thrombospondin fragments found in plasma, their use or use of portions thereof in diagnostic methods, as method calibrators, method indicators, and as immunogens, and as analytes for methods with substantial clinical utility; and their detection in plasma or other bodily fluids for purpose of diagnostic methods, especially for cancer. | 02-20-2014 |
| 20140051099 | DIAGNOSIS AND TREATMENT OF ANGIOEDEMA - The present patent application relates to a method for diagnosing angioedema with a gain-of-function mutation of kinin formation, and for determining the amount of BK or des-Arg | 02-20-2014 |
| 20140057297 | Antibodies to Paliperidone Haptens and Use Thereof - Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, risperidone and paliperidone in a single lateral flow assay device. | 02-27-2014 |
| 20140057298 | Antibodies to Paliperidone and Use Thereof - Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone/paliperidone in a single lateral flow assay device. | 02-27-2014 |
| 20140057299 | Antibodies to Aripiprazole Haptens and Use Thereof - Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device. | 02-27-2014 |
| 20140057300 | Antibodies to Aripiprazole and Use Thereof - Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device. | 02-27-2014 |
| 20140057301 | Antibodies to Risperidone Haptens and Use Thereof - Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device. | 02-27-2014 |
| 20140057302 | Antibodies to Risperidone and Use Thereof - Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone in a single lateral flow assay device. | 02-27-2014 |
| 20140057303 | Antibodies to Olanzapine Haptens and Use Thereof - Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device. | 02-27-2014 |
| 20140057304 | Antibodies to Olanzapine and Use Thereof - Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device. | 02-27-2014 |
| 20140057305 | Antibodies to Quetiapine Haptens and Use Thereof - Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device. | 02-27-2014 |
| 20140057306 | Antibodies to Quetiapine and Use Thereof - Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone in a single lateral flow assay device. | 02-27-2014 |
| 20140178908 | IMMUNOASSAY AND IMMUNOASSAY APPARATUS - A method of competitive immunoassay is provided. The method comprising: creating a first calibration curve created for a first reaction time period and a second calibration curve created for a second reaction time period longer than the first reaction time period; preparing a measurement sample containing a target substance in a specimen, a reactant, and a competitive substance; obtaining a reference information related to the concentration of the target substance after the first reaction time period since the preparation of the measurement sample; first outputting the concentration obtained based on the first calibration curve as a measurement result in the case where the reference information shows that the concentration of the target substance is less than a predetermined threshold; and second outputting the concentration obtained based on the second calibration curve as the measurement result in the case where the reference information obtained in the obtaining is information showing that the concentration of the target substance is more than or equal to the threshold. | 06-26-2014 |
| 20140248643 | CHROMATOGRAPHIC PROCESS FOR ENRICHMENT AND ISOLATION - A chromatographic process for the enrichment of at least one compound of interest from a mixture is proposed, using chromatographic columns, wherein said process involves a sequence of the following steps: (i) a cyclic accumulation phase, in which the chromatographic columns are alternatingly operated in an interconnected phase, followed by a disconnected phase, wherein subsequently columns exchange places and wherein the phases are carried out sequentially; (ii) a cyclic separation phase, in which the chromatographic columns are alternatingly operated in an interconnected phase, followed by a disconnected phase, wherein after these phases columns exchange places to undergo the next interconnected and disconnected phases; and (iii) an elution phase, in which from the column, which at the end of phase (i) or at the end of phase (ii) contains the compound of interest, is extracted via the outlet. | 09-04-2014 |
| 20140273034 | ELECTROCHEMICAL METHODS AND DEVICES FOR AMENDING URINE SAMPLES FOR IMMUNOSENSOR DETECTION - The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step. | 09-18-2014 |
| 20140295468 | TEST SUBSTANCE ASSAY METHOD, TEST SUBSTANCE ASSAY KIT, AND TEST SUBSTANCE ASSAY REAGENT - The test substance assay method includes (i) obtaining a mixed solution by mixing (a) first dry particles that are modified with first binding substances exhibiting binding properties specific to a test substance, have an average particle size of 100 nm to 200 nm, and have labels, and (b) second dry particles that are modified with second binding substances not exhibiting binding properties specific to the test substance, have an average particle size of 100 nm to 200 nm, and do not have labels with (c) a test sample solution containing the test substance; (ii) applying the mixed solution onto a substrate; (iii) causing the test substance to be trapped in a reaction site on the substrate that has third binding substances having binding properties specific to the test substance or has substances exhibiting binding properties to the first binding substances; and (iv) detecting the test substance. | 10-02-2014 |
| 20140295469 | In Vitro Assessment of Cardiovascular Events by Assay for Neo-Eptitopes of Titin Protein - A bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a titin protein by a proteinase comprises contacting a sample with an antibody specifically binding said neo-epitope and determining the level of binding. Partial sequences of titin that may be detected include: | 10-02-2014 |
| 20150037823 | BIOMARKER FOR OSTEOARTHRITIS AND/OR OTHER AGEING-RELATED DISEASES, AND USE THEREOF - The invention relates to the identification of a biomarker whose abundance in biological sample is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases. | 02-05-2015 |
| 20150118698 | Biochemical Markers for CVD Risk Assessment - A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage ofmimecan, a protein of an atherosclerotic plaque, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events. | 04-30-2015 |
| 20150301051 | IN VITRO POTENCY ASSAY FOR PROTEIN-BASED MENINGOCOCCAL VACCINES - The invention uses ELISA or similar assays for analysing a meningococcal vaccine. The assay uses antibodies which bind to meningococcal proteins within the vaccine, and in particular monoclonal antibodies which are bactericidal for meningococcus and/or which recognise conformational epitopes within the meningococcal proteins. By performing the assay on a series of dilutions of a test vaccine, and by comparing the results with those obtained using a reference vaccine of known potency, it is possible to determine the relative potency of the test vaccine. This value can be used as a parameter for determining whether a manufactured batch of a vaccine is suitable for release to the public, or whether it has experienced a production failure and so should not be used. | 10-22-2015 |
| 20150301065 | Determining Pathological Cartilage Turnover - The present embodiments relate to methods for determining or detecting pathological cartilage turnover by detection of Cartilage Oligomeric Matrix Protein (COMP) neoepitopes, both released into body fluids and present in the tissue. Furthermore the embodiments relate to antibodies against COMP neoepitopes and to fragments and peptides containing COMP neoepitopes for generation of such antibody. | 10-22-2015 |
| 20150346223 | FT4 ELECTROCHEMICAL ASSAY DETECTION SYSTEM - Some embodiments provide a method for performing a free thyroxin assay. The method may include providing a flow cell that may include a plurality of sensors at least partially coated with a plurality of antibodies that bind to free thyroxin. The method may further provide introducing a sample into the flow cell so that the sample contacts the sensors, and incubating the sample therein for a time. As a result, at least a portion of any free thyroxin within the sample can bind at least some of the antibodies. In addition the method may include introducing a wash agent into the flow cell to clear the flow cell of any substantial amount of the sample. | 12-03-2015 |
| 20150355171 | INDOXYL SULFATE MEASUREMENT METHOD - An object of the present invention is to provide a competitive EIA method capable of quantitatively measuring indoxyl sulfate in blood. The problem described above can be solved by an indoxyl sulfate measurement method based on a competitive method comprising: (1) a step in which albumin in a specimen is pretreated; (2) a specimen-antibody reaction step in which the pretreated specimen and anti-indoxyl sulfate antibodies are brought into contact with each other in the substantial absence of exogenous mammalian albumin; (3) an immobilized IS-antibody reaction step in which the specimen-antibody reaction solution is brought into contact, in the substantial absence of exogenous mammalian albumin, with an immobilized insoluble support in which indoxyl sulfate is immobilized and then blocked with a buffer solution containing substantially no mammalian albumin; and (4) a step in which anti-indoxyl sulfate antibodies which have bonded to the immobilized insoluble support are detected. | 12-10-2015 |
| 20150355174 | METHOD FOR CAPTURING, METHOD FOR DETECTING AND KIT FOR CAPTURING A MOLECULE IN A SAMPLE - A method for capturing a molecule in a sample, comprising mixing the sample with magnetic particles. Each of the particles being coupled with an element capable of binding selectively to the molecule for capture, so as to form at least one complex comprising a magnetic particle. The element and the molecule bound to the element, immobilizing the at least one complex on a support comprising ordered magnetic field microsources. | 12-10-2015 |
| 20150377877 | ANALYTICAL IMMUNOSENSOR DEVICE AND METHOD FOR CONSTRUCTING SAME - Analytical immunosensor device and method for obtaining thereof based on sequential deposition of self-assembled monolayers of polymers and affinity elements and their uses for the detection and quantitation of any analyte or target antigen in a liquid sample, allowing to perform the analysis by quasi-reagentless or reagentless displacement assay, and minimizing nonspecific adsorption and thus decreasing the detection limit. The device is arranged from a sensor surface covered with polymer monolayers (redox or non-redox) on top of which submonolayers of affinity elements are deposited and then, to let the affinity reaction to take place with the antigen, pseudo-antigen or the hapten labelled with a protein, preferably an enzyme (redox or non-redox), or with a nanoparticle enabling the method of the invention to develop “ad hoc” immunosensors, with a signal transduction by electrochemical, optical and/or piezoelectric means. | 12-31-2015 |
| 20160033489 | Haptenes and Conjugates Derived from Pyocyanin, Antibodies Thereof, and Immunichemical Method for Detecting Infections Caused by Pseudomonas Aeruginosa - The present invention relates to a compound of general formula I and to the use thereof as a hapten. | 02-04-2016 |
| 20160084859 | DETECTION OF INDAZOLE SYNTHETIC CANNABINOIDS - Components for enabling immunodection of indazole synthetic cannabinoids are described including immunogens, haptens, antibodies, methods and kits. | 03-24-2016 |
| 20160109439 | MAGNETIC IMMUNOSENSOR AND METHOD OF USE - The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field. | 04-21-2016 |
| 20160109461 | FEN1 AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein FEN1 in said sample in vitro. | 04-21-2016 |
| 20160145327 | Compositions, Devices, Kits and Methods for Detecting Hookworm - Methods, devices, kits and compositions for detecting the presence or absence of hookworm in a fecal sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of hookworm in a fecal sample from a mammal that may also be infected with one or more of roundworm, whipworm, and heartworm. Confirmation of the presence or absence of hookworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated. | 05-26-2016 |
| 20160161489 | Urine-based immuncassay for urocirtub 3 abd duagbisus if skeeo aobea - The present invention provides a method of identifying and isolating a set of monoclonal and polyclonal antibodies for use in immunometric assays for the detection of UCN III peptide, and the development of a two-site immunoassay for UCN III peptide. Monoclonal antibodies (mAb) have been affinity purified and used to develop a two-site immunometric assay comprising a mAb selected from the list comprising 2F7, 4E3, 4D3, 6D1, 1G10, 2E7, 4F3, 4C3, 5E11, 1A9, 4C4, 4B4, 2G7, 2A4, 1B9, 3H11, 5F2, 4G2, and 2E3 used for capture and a polyclonal antibody used for detection. The immunometric assay of the present invention comprise a method to identify and isolate specific antibodies or fragments thereof establishing the presence and/or amount of a UCN III peptide and detecting the specific binding necessary for determining a sample's UCN III peptide level for correlation with a diagnosis wherein the UCN III peptide level is used to determine whether the subject suffers from OSA. | 06-09-2016 |
| 20160178631 | METHODS FOR THE EARLY DETECTION OF COLORECTAL CANCER | 06-23-2016 |
| 20160202276 | SOLUTION FOR DISSOCIATING VITAMIN D FROM VITAMIN D-BIDING PROTEIN, ASSOCIATED DETECTION METHOD AND USE | 07-14-2016 |
| 20170234865 | Methods, Compositions and Devices for Improving the Sensitivity of Assays | 08-17-2017 |
| 20180022827 | ANTIBODIES TO RISPERIDONE HAPTENS AND USE THEREOF | 01-25-2018 |
| 20220137051 | IN-VITRO POTENCY ASSAY FOR PROTEIN-BASED MENINGOCOCCAL VACCINES - The invention uses ELISA or similar assays for analysing a meningococcal vaccine. The assay uses antibodies which bind to meningococcal proteins within the vaccine, and in particular monoclonal antibodies which are bactericidal for meningococcus and/or which recognise conformational epitopes within the meningococcal proteins. By performing the assay on a series of dilutions of a test vaccine, and by comparing the results with those obtained using a reference vaccine of known potency, it is possible to determine the relative potency of the test vaccine. This value can be used as a parameter for determining whether a manufactured batch of a vaccine is suitable for release to the public, or whether it has experienced a production failure and so should not be used. | 05-05-2022 |
